Skip to content

Advertisement

  • Poster presentation
  • Open Access

Bone mass predictors in a large cohort of children with juvenile idiopathic arthritis (JIA)

  • 1,
  • 1,
  • 3,
  • 1,
  • 2,
  • 2 and
  • 2
Pediatric Rheumatology20086 (Suppl 1) :P66

https://doi.org/10.1186/1546-0096-6-S1-P66

  • Published:

Keywords

  • Bone Mineral Density
  • Bone Mass
  • Disease Duration
  • Juvenile Idiopathic Arthritis
  • Juvenile Idiopathic Arthritis Patient

Purpose

Low bone mass has been reported in children with JIA. We wanted to assess areal bone mineral density (BMD) in our cohort of patients and correlate the results with clinical data.

Methods

The study population included 162 pts (113 F and 49 M, mean age 10.6 ± 3.1 yrs) affected with JIA: 77 oligoarticular, 48 polyarticular RF-, 15 systemic, and 22 enthesitis-related arthritis (ERA) onset. All patients underwent bone mass evaluation by DXA at lumbar spine (L2–L4). DXA values were correlated with JIA category, age at onset, disease duration, ESR, CRP, flare rate, and medications. Age- and sex-specific reference values from an age-matched healthy population were used to calculate z-scores. Two-way analysis of variance was used to determine whether the DXA z-score correlated with disease category, medications, age at onset, disease duration.

Results

The whole group of JIA pts showed lower DXA z-scores (systemic p = 0.0012; oligoarticular p = 0.0072; polyarticular p = 0.0002), except ERA (p = NS) when compared to controls. DXA z-scores significantly correlated with JIA subtype: systemic had lower z-score than oligoarticular (p = 0.015) and ERA (p = 0.001), while polyarticular pts had lower z-score in comparison to ERA (p = 0.009).

In the group with oligoarticular onset, patients treated with MTX plus corticosteroids had a higher z-score than those treated with only corticosteroids (p = 0.024).

Conclusion

JIA patients, in particular with polyarticular and systemic onset show a lower DXA z-score in comparison to controls while in ERA DXA values are comparable to controls. Together with sex, disease duration seems the main factor modifying DXA value.

Authors’ Affiliations

(1)
Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Florence, Italy
(2)
Department of Paediatrics, Rheumatology and Endocrinology Units, University of Florence, Florence, Italy
(3)
Oncology Prevention Unit and CSPO, University of Florence, Florence, Italy

Copyright

Advertisement